vardenafil and zaprinast share 5 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.625 means 63% of the combined target set is bound by both compounds. The IDF-weighted score of 0.659 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do vardenafil and zaprinast have in common?
vardenafil and zaprinast share 5 molecular targets with a Jaccard similarity of 63%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can vardenafil and zaprinast be combined?
vardenafil and zaprinast share 5 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: vardenafil or zaprinast?
In the BiohacksAI corpus: vardenafil has 0 PubMed-indexed studies, zaprinast has 0 studies.